Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
20.88
-1.14 (-5.18%)
At close: May 15, 2026, 4:00 PM EDT
20.68
-0.20 (-0.96%)
After-hours: May 15, 2026, 7:26 PM EDT
Immunome Revenue
Immunome had revenue of $4.01M in the twelve months ending March 31, 2026, down -63.29% year-over-year. In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$4.01M
Revenue Growth
-63.29%
P/S Ratio
588.96
Revenue / Employee
$22,684
Employees
177
Market Cap
2.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Zai Lab | 453.28M |
| IDEAYA Biosciences | 225.27M |
| Nektar Therapeutics | 55.63M |
| Relay Therapeutics | 10.68M |
| Celldex Therapeutics | 865.00K |
IMNM News
- 1 day ago - Immunome price target lowered to $33 from $37 at Leerink - TheFly
- 3 days ago - Immunome reports Q1 EPS (48c), consensus (54c) - TheFly
- 3 days ago - Immunome Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 10 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Immunome announces submission of NDA for varegacestat in desmoid tumors - TheFly
- 17 days ago - Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors - Business Wire
- 25 days ago - Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting - Business Wire
- 4 weeks ago - Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead - FXEmpire